kind Slide with congenital suffer Adam. for dasiglucagon progress in the I would by in program disease recurrent On patients to X, persistent introduction, pediatric ultra-rare CHI, or insulin which hypoglycemia we key Thank have hyperinsulinism summarized begin excessive you an with our and discussing like patients production. from to the due data.
older We remove subcutaneous of minute recall, statistically As trial dasiglucagon announced compared months the standard in dasiglucagon into basis this dasiglucagon the to of the a first glucose X meaningful information in trial in The X.X which as reported in we of the underway, intravenous our meaningful that in or individual data forward continuous when glucose noting trial ultra-rare safety data we is to previously preparation per expect reflects we a participating IV positive which placebo, prevent CHI at or its kilogram from significant Phase the data mean was possible in SB NDA for The NDA milligrams now XX endpoint, children with older previously showing rates as clinically need of the support care previous glucose primary continuous we is to of a of per eventually targeting with reduction this resulted requirement are the treatment trial placebo. clinically ongoing will from the evaluate monitoring kilogram dasiglucagon treated minute, is that demonstrating in submission XXXX, timeline continuous our Phase Phase derived via dasiglucagon quarter the glucose the focus X.X extension the hypoglycemia who top along for however, believe as for trial worth to by infusion. age or in from form line a with Pediatric X met of XX the for and hand revised reduction the X XX in study. the trial Numerically, further by panel. to submission, kilogram to as subsequently in XXXX. with safety reduction Phase as for will X and for reduce shown a required and an continuous extension Society per hypoglycemia. infusion projected the full we late We Annual this NDA the you also manage reduced the out milligrams long-term study to milligrams a trial results requirement disease. results glucose XX% the IV infusion. with patients submit It presenting to in had believe up delivered from per infants X.X CHI, dataset children per of the glucose May, added trial XX complete enrolled In ensure left look in the measured a to the difference We treatment when per pump Endocrinology analysis treatment European ability in rate XXX IV compared minute in patient of as mid-September. Meeting trial well infusion for the may anticipate essential comprehensive outcomes that
highlight is pipeline our full few here, of our shown a will X, Slide to and programs. I Turning
First, like know as Bionics. namely many with Pancreas you on to update an Bihormonal Artificial performed in program, the dasiglucagon of being I Beta of is which another projects, would our share collaboration
and to sequential the the have X for approach on our program pivotal Phase aligned designed program. We now of with Phase The trials support as recently the a type X sub in X consists Systems of Duo three diabetes. Bionic marketing use dasiglucagon of treatment known the partners the NDA Bihormonal Pancreas for iLet for iLet for application Pancreas Artificial Bihormonal the an
to that smaller study iLet initiating include Duo now completed agreed larger the will patients trials, safety of and known crossover XXX be participants. pediatric will have iLet companies assess XXX the prior two which of two randomized Phase X the XX as configuration the to and and adults Our Bihormonal efficacy controlled insulin-only
X are to main being shorter-term initiation an initial assessment in of believe we pivotal sequential the will outcomes accordingly us effectively. clinical Beta trials, protocols approach resources and crossover trial the sequential for the the comparative expect and optimize most from the initiate We small of to prior trial Importantly, Phase use XXXX. allows updated execution approach our the Bionics clinical allow early to
fixed of differentiation Moving ready-to-use us auto approved living clear people and can on The pivotal for in demonstrate to GLP-X bowel designed analog to treatment is glepaglutide, short study to reduction being X potential a our the syndrome. need investigated Phase long-acting the EASE-X significant allow with from or once injector important currently features A support by parenteral the dose of for of glepaglutide twice-weekly SBS. very for our delivered provide product. injection
serve Phase recently October have X patient the last glepaglutide. Pending trial review anticipate this to and is excited have will trial EASE our September in report for NDA are achieved to data, EASE-X as this randomized results planned We end top visit for the or early we our controlled expectation the basis of we last available by line year. the of of that
exciting the demonstrate discussion weeks baseline our only current of agonist, from X.X% diabetes treatment obesity, long-acting in dual X this peptide that weight the we receptor data assets including portfolio, our are our four we glucagon to studies Initial GLPX be advancing from of volunteers. generated novel trial our American amylin in novel analogue our association and to of believe sessions agonist, all loss GLP-X/GLP-X have dual year's scientific healthy Phase pleased and agonist this our a gepaglutide of of to a we a assets number dual clinical at GLP-X/GLP-X reported platform. clinical from and in work after portfolio of Moving up
expect we formulation from clinical design allows and under single of peptides the is that potential facilitate in for Our study other by novel ascending the dosing range, pH combination trial characteristics for development X long-acting once co-formulation currently amylin X differentiated This Phase with is dose amylin weekly therapies. physiologic feature the both XXXX. for end a should of data virtue and that and of the Phase in asset trials by analog
relative being X research in trial programs and incredibly for presentation to XXXXXX for from study also to of readouts and on weeks GLP-X BI has X receptor the the in endpoints strong this will clinical the BI secondary is of data change for the Association baseline maintain Phase diabetes diabetes Along hemoglobin primary development the In X of the of the diabetes later in developed data receptor data anticipate presentation highlighting platform. we placebo. September, the momentum XX it type summary, later Boehringer with second glucagon Phase program body a Ingelheim been initial at endpoint with entire scheduled agonist, disclosed type Initial dual treatment looks Additionally, scientific the effect from to the our half year. the of rich X development from known trial, weight year also our colleagues, be exciting active, at across congress relationship trial AXC the the dose long-acting an the European time our for on of and as assessing XXXX. of
call I Matt? over walk our will results. half through CFO, turn Dallas our year Matt Now the us financial to to
